Change in lung function following 4 weeks of nebulised antibiotic therapy
| Assessment | FEV1 % pred % change from baseline | p-value¶ | |
| TNS | Colistin | ||
| ITT population | |||
| Patients at week 4 n | 50 | 59 | |
| Mean±sd | 6.70±15.12 | 0.37±18.78 | 0.008 |
| p-value (within)# | 0.006 | 0.473 | |
| Age group 6–12 | |||
| Patients at week 4 n | 11 | 11 | |
| Mean±sd | 11.51±24.33 | −8.11±18.38 | |
| p-value (within)# | 0.148 | 0.17 | |
| Age group 13–17 | |||
| Patients at week 4 n | 11 | 14 | |
| Mean±sd | 14.43±7.32 | 6.01±25.78 | |
| p-value (within)# | <0.001 | 0.399 | |
| Age group >18 | |||
| Patients at week 4 n | 28 | 34 | |
| Mean±sd | 1.77±10.80 | 0.79±14.75 | |
| p-value (within)# | 0.393 | 0.757 | |
TNS: tobramycin nebuliser solution
ITT: intent-to-treat
FEV1: forced expiratory volume in one second
#: within-group paired t-testing
¶: between-group testing using Wilcoxon rank-sum test